Violation Tracker Individual Record
Date:March 23, 2016
Primary Offense:Foreign Corrupt Practices Act
The Securities and Exchange Commission announced that Novartis AG agreed to pay $25 million to settle charges that it violated the Foreign Corrupt Practices Act when its China-based subsidiaries engaged in pay-to-prescribe schemes to increase sales.
Level of Government:federal
Action Type:agency action
Agency:Securities and Exchange Commission
Civil or Criminal Case:civil
HQ Country of Parent:Switzerland
Ownership Structure of Parent:publicly traded
Major Industry of Parent:pharmaceuticals
Specific Industry of Parent:pharmaceuticals
Source of Data:
Source Notes:If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.